Style | Citing Format |
---|---|
MLA | Matin N, et al.. "Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications." Human Vaccines and Immunotherapeutics, vol. 11, no. 8, 2015, pp. 2021-2029. |
APA | Matin N, Tabatabaie O, Falsaperla R, Lubrano R, Pavone P, Mahmood F, Gullotta M, Serra A, Di Mauro P, Cocuzza S, Vitaliti G (2015). Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications. Human Vaccines and Immunotherapeutics, 11(8), 2021-2029. |
Chicago | Matin N, Tabatabaie O, Falsaperla R, Lubrano R, Pavone P, Mahmood F, Gullotta M, et al.. "Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications." Human Vaccines and Immunotherapeutics 11, no. 8 (2015): 2021-2029. |
Harvard | Matin N et al. (2015) 'Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications', Human Vaccines and Immunotherapeutics, 11(8), pp. 2021-2029. |
Vancouver | Matin N, Tabatabaie O, Falsaperla R, Lubrano R, Pavone P, Mahmood F, et al.. Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications. Human Vaccines and Immunotherapeutics. 2015;11(8):2021-2029. |
BibTex | @article{ author = {Matin N and Tabatabaie O and Falsaperla R and Lubrano R and Pavone P and Mahmood F and Gullotta M and Serra A and Di Mauro P and Cocuzza S and Vitaliti G}, title = {Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications}, journal = {Human Vaccines and Immunotherapeutics}, volume = {11}, number = {8}, pages = {2021-2029}, year = {2015} } |
RIS | TY - JOUR AU - Matin N AU - Tabatabaie O AU - Falsaperla R AU - Lubrano R AU - Pavone P AU - Mahmood F AU - Gullotta M AU - Serra A AU - Di Mauro P AU - Cocuzza S AU - Vitaliti G TI - Epilepsy and Innate Immune System: A Possible Immunogenic Predisposition and Related Therapeutic Implications JO - Human Vaccines and Immunotherapeutics VL - 11 IS - 8 SP - 2021 EP - 2029 PY - 2015 ER - |